Intellia Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Intellia Therapeutics
NTLA Stock  USD 7.41  0.64  9.45%   
Intellia Therapeutics financial statements provide useful quarterly and yearly information to potential Intellia Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Intellia Therapeutics financial statements helps investors assess Intellia Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Intellia Therapeutics' valuation are summarized below:
Gross Profit
-408.4 M
Market Capitalization
767.1 M
Enterprise Value Revenue
6.4922
Revenue
57.9 M
Earnings Share
(5.25)
We have found one hundred twenty available fundamental trends for Intellia Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Intellia Therapeutics regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Intellia Therapeutics Total Revenue

35.95 Million

Check Intellia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intellia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.5 M, Interest Expense of 10.3 M or Selling General Administrative of 132.1 M, as well as many indicators such as Price To Sales Ratio of 18.92, Dividend Yield of 0.0 or PTB Ratio of 2.58. Intellia financial statements analysis is a perfect complement when working with Intellia Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Intellia Therapeutics Correlation against competitors.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.

Intellia Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets743.3 M1.2 B513.7 M
Slightly volatile
Other Current Liabilities58.1 M55.4 M21.3 M
Slightly volatile
Total Current Liabilities69.4 M110.9 M48.3 M
Slightly volatile
Total Stockholder Equity585.8 M872 M404.6 M
Slightly volatile
Other Liabilities38.1 M50.6 M27.9 M
Slightly volatile
Property Plant And Equipment Net259 M246.7 M65.9 M
Slightly volatile
Accounts Payable15.3 M14.6 M4.9 M
Slightly volatile
Cash203.8 M189.2 M142.6 M
Slightly volatile
Non Current Assets Total578.7 M551.2 M153.3 M
Slightly volatile
Non Currrent Assets Other314.2 M299.2 M67.5 M
Slightly volatile
Other Assets19 M18.1 M6.4 M
Slightly volatile
Cash And Short Term Investments575.2 M601.5 M397.9 M
Slightly volatile
Common Stock Total Equity7.7 K8.1 K209.6 K
Slightly volatile
Common Stock Shares Outstanding55.8 M98.8 M38.5 M
Slightly volatile
Liabilities And Stockholders Equity743.3 M1.2 B513.7 M
Slightly volatile
Non Current Liabilities Total218.6 M208.2 M68.9 M
Slightly volatile
Other Current Assets18 M29.8 M12.5 M
Slightly volatile
Other Stockholder Equity3.2 B3 B989 M
Slightly volatile
Total Liabilities335 M319.1 M120.1 M
Slightly volatile
Property Plant And Equipment Gross311.2 M296.4 M78.5 M
Slightly volatile
Total Current Assets556 M639.9 M384.8 M
Slightly volatile
Common Stock9.5 K10 K209.8 K
Slightly volatile
Property Plant Equipment18.1 M32.1 M14.2 M
Slightly volatile
Current Deferred Revenue28.7 M20.7 M20.1 M
Slightly volatile
Net Receivables9.1 M8.5 M6.1 M
Slightly volatile
Capital Surpluse2.9 B2.8 B937.1 M
Slightly volatile
Deferred Long Term Liabilities38.9 M50.7 M29.9 M
Slightly volatile
Non Current Liabilities Other29 M27.6 M11.2 M
Slightly volatile
Net Invested Capital766.3 M872 M527.7 M
Slightly volatile
Net Working Capital627 M529 M465.7 M
Slightly volatile
Capital Stock8.2 K10 K6.3 K
Slightly volatile
Short and Long Term Debt Total107.8 M210.2 M53.8 M
Slightly volatile
Capital Lease Obligations107.8 M210.2 M53.8 M
Slightly volatile
Long Term Investments189.9 M304.5 M79.3 M
Slightly volatile
Short Term Debt20.2 M20.2 M14.6 M
Slightly volatile

Intellia Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.5 M10.3 M3.7 M
Slightly volatile
Selling General Administrative132.1 M125.8 M45.3 M
Slightly volatile
Other Operating Expenses621.7 M592.1 M204.8 M
Slightly volatile
Research Development489.6 M466.3 M159.6 M
Slightly volatile
Cost Of Revenue9.8 M10.3 M31.9 M
Pretty Stable
Total Operating Expenses621.7 M592.1 M204.3 M
Slightly volatile
Net Interest Income50.2 M47.8 M11.1 M
Slightly volatile
Interest Income50.2 M47.8 M11.1 M
Slightly volatile
Reconciled Depreciation7.3 M10.3 M5.1 M
Slightly volatile

Intellia Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation161.9 M154.2 M41.6 M
Slightly volatile
Capital Expenditures13.5 M16.1 M9.5 M
Slightly volatile
Total Cash From Financing Activities252.4 M185.7 M178.3 M
Slightly volatile
End Period Cash Flow212.7 M276.4 M152.2 M
Slightly volatile
Change To Netincome207.4 M197.6 M57.4 M
Slightly volatile
Begin Period Cash Flow646.6 M615.8 M184.5 M
Slightly volatile
Issuance Of Capital Stock168.1 M176.9 M176 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio18.9219.914358.6378
Very volatile
PTB Ratio2.581.32182.7347
Slightly volatile
Days Sales Outstanding76.9753.712383.812
Pretty Stable
Book Value Per Share8.018.821111.2768
Slightly volatile
Stock Based Compensation To Revenue2.432.31610.9477
Slightly volatile
PB Ratio2.581.32182.7347
Slightly volatile
EV To Sales19.2620.277451.0632
Very volatile
Payables Turnover1.321.3910.5464
Pretty Stable
Sales General And Administrative To Revenue1.242.17411.4748
Slightly volatile
Research And Ddevelopement To Revenue8.468.05694.1981
Slightly volatile
Capex To Revenue0.30.24160.3849
Very volatile
Cash Per Share11.266.085212.8069
Slightly volatile
Days Payables Outstanding286273125
Slightly volatile
Current Ratio6.385.77236.9507
Slightly volatile
Tangible Book Value Per Share8.018.821111.2768
Slightly volatile
Receivables Turnover7.176.79557.9355
Pretty Stable
Shareholders Equity Per Share8.018.821111.2768
Slightly volatile
Debt To Equity0.250.24110.0958
Slightly volatile
Capex Per Share0.130.14150.4169
Slightly volatile
Graham Net Net2.782.92218.5287
Slightly volatile
Revenue Per Share0.730.58550.5651
Slightly volatile
Interest Debt Per Share2.232.12650.8188
Slightly volatile
Debt To Assets0.190.17650.0754
Slightly volatile
Price Book Value Ratio2.581.32182.7347
Slightly volatile
Days Of Payables Outstanding286273125
Slightly volatile
Ebt Per Ebit1.260.97151.5429
Slightly volatile
Company Equity Multiplier1.421.36591.3271
Slightly volatile
Long Term Debt To Capitalization0.140.160.1753
Slightly volatile
Total Debt To Capitalization0.20.19420.0851
Slightly volatile
Debt Equity Ratio0.250.24110.0958
Slightly volatile
Quick Ratio6.635.77237.1868
Slightly volatile
Net Income Per E B T0.770.930.9341
Very volatile
Cash Ratio1.621.70663.9813
Slightly volatile
Days Of Sales Outstanding76.9753.712383.812
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.311.191.1896
Very volatile
Price To Book Ratio2.581.32182.7347
Slightly volatile
Fixed Asset Turnover0.220.23461.3752
Slightly volatile
Debt Ratio0.190.17650.0754
Slightly volatile
Price Sales Ratio18.9219.914358.6378
Very volatile
Asset Turnover0.07010.04860.0672
Slightly volatile
Price Fair Value2.581.32182.7347
Slightly volatile

Intellia Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.6 M9.7 M10.5 M
Slightly volatile
Enterprise Value714.4 K803.7 K876.2 K
Slightly volatile

Intellia Fundamental Market Drivers

Cash And Short Term Investments601.5 M

Intellia Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Intellia Therapeutics Financial Statements

Intellia Therapeutics stakeholders use historical fundamental indicators, such as Intellia Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Intellia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Intellia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Intellia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Intellia Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue20.7 M28.7 M
Total Revenue57.9 M35.9 M
Cost Of Revenue10.3 M9.8 M
Stock Based Compensation To Revenue 2.32  2.43 
Sales General And Administrative To Revenue 2.17  1.24 
Research And Ddevelopement To Revenue 8.06  8.46 
Capex To Revenue 0.24  0.30 
Revenue Per Share 0.59  0.73 
Ebit Per Revenue(9.23)(9.69)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ZLABZai Lab
ASLEAerSale Corp
ATSAT S Austria
When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:
How To Invest In Intellia
Details
Is Intellia Stock a good investment?
Details
What is Intellia Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Intellia Therapeutics Correlation against competitors.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.25)
Revenue Per Share
0.586
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.27)
Return On Equity
(0.54)
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY